Cornea

Christopher E. Starr, MD, FACS, highlights diagnostic gaps in dry eye, emphasizing neuropathic corneal pain and reviewing emerging therapies and pipeline treatments in ocular surface disease.

Understanding thyroid eye disease and its often-missed diagnosis.

CMS assigns billing code to support reimbursement for the keratoconus therapy.

The trial is evaluating AURN001, a single-administration regenerative cell therapy for corneal edema secondary to corneal endothelial dysfunction

Engineered ocular bacteria act as a long-lasting eye drop, secreting IL-10 to speed corneal healing and hint at future living therapies.

The phase 3 study was a randomized, double-masked, placebo-controlled, multicenter trial evaluating subcutaneous teprotumumab administered every 2 weeks for 24 weeks.

Immunovant, along with partner HanAll, will assess future plans for the development of batoclimab and provide an update at a future, unspecified date

Five-year pediatric Boston KPro results show vision gains, but low retention and high membrane, melt and glaucoma risks persist.

Phase 3 shows epi-on oxygen CXL flattens pediatric keratoconus, improves vision, and stays well tolerated—now commercially available.

An off-the-shelf corneal cell injection targets FECD and bullous keratopathy, aiming to restore vision and ease donor shortages.

QoL areas measured included enjoying relationships/life, overall mood, and time spent thinking of eye pain.

The 3rd Winterthur Ophthalmology Symposium in Winterthur, Switzerland, on 12–13 March 2026 will feature plenary talks, hands-on workshops, satellite sessions, poster presentations, and a gala honoring the Otto Haab Medal.

The clinical study will evaluate a noninvasive corneal strengthening procedure designed to reshape the cornea and correct refractive errors in-office without tissue removal.

FDA clears DifGen’s generic fluorometholone 0.1% eye drop suspension, expanding lower-cost options for anterior eye inflammation and steroid care.

Interventional therapies give patients faster relief and better outcomes

Retina experts unpack MacTel type 2—spot subtle signs, understand anti-VEGF limits, and explore emerging neuroprotective treatments.

FDA feedback backs urcosimod’s Phase 2b/3 plan for neuropathic corneal pain, defining a meaningful pain endpoint in an unmet field.

FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and sensitivity of the eyes, face, or head.

Post‑Pfizer mRNA shots show short‑term corneal thickening and lower endothelial cell density, prompting closer monitoring for graft or low‑count patients.

Patients underwent a full ophthalmologic examination that included optical coherence tomography (OCT), OCT angiography, and biometry.